Company Overview
INVO Fertility, Inc. operates as a healthcare services company dedicated to the fertility marketplace, delivering assisted reproductive technology care to patients through its specialized segments. The company organizes its operations across three distinct areas: Fertility Clinic Services, the INVOcell Device, and Therapeutics, where it provides the INVOcell Device, a specific medical device. Situated within the Healthcare sector and specifically the Medical Devices industry, the firm focuses on providing technological solutions and clinical services to support reproductive health needs. Currently, the company maintains a market capitalization of $18.66M and generates annual revenue of $6.94M while employing a workforce of 33 individuals. These valuation and revenue figures indicate that INVO Fertility, Inc. functions as a small-cap entity with a relatively narrow operational footprint compared to larger diversified healthcare conglomerates.
Financial Health
The company reported revenue of $6.94M over the trailing twelve months, yet this generated a net income of $-11,220,118 and an EBITDA of $-7,119,142. The substantial disparity between the positive revenue of $6.94M and the significant negative net income reveals a cost structure characterized by high operating expenses or non-operating charges that consume the majority of top-line earnings. Despite the negative net income and EBITDA, the company posted a free cash flow of $950,669, which suggests a degree of financial flexibility allowing for operational continuity despite accounting losses. The company holds cash reserves of $355,891 against total debt of $4.23M, resulting in a debt-to-equity ratio of 72.39. This balance sheet configuration indicates a highly leveraged position where debt obligations significantly outweigh liquid cash holdings. The current ratio stands at 0.12, a metric that signals severe short-term liquidity constraints as current assets are insufficient to cover current liabilities. Additionally, the return on equity is listed as N/A due to the negative equity base, while the return on assets is -48.4%, indicating that the asset base is currently generating negative returns. The gross margin is 39.2%, whereas the operating margin is -93.1% and the profit margin is 0.0%, highlighting a scenario where core operations are not covering overhead costs effectively enough to generate a bottom-line profit.
Valuation Assessment
The trailing P/E ratio is N/A because the company has not generated positive earnings over the trailing twelve months, while the forward P/E is listed at -0.12. The difference between these metrics, specifically the negative forward valuation, implies that the market anticipates a continued lack of profitability in the near term rather than an immediate earnings turnaround. The price-to-book ratio is -0.12, a figure that indicates the market is valuing the company at a significant discount relative to its book value, reflecting the negative equity position. Alternatively, the price-to-sales ratio is 2.69 and the EV/EBITDA is -1.93, suggesting that valuation is being assessed primarily on revenue generation rather than earnings power or cash flow multiples. The stock has traded between a 52-week low of $0.68 and a 52-week high of $76.80. Without the specific current share price to calculate the exact percentage, the trading range demonstrates extreme volatility, with the stock capable of moving more than 10,000% from its low to its high within a single year. The beta value is N/A, meaning there is no available data to quantify the stock's price volatility relative to the broader market movements.
Growth & Income
Revenue growth over the past year was 22.6%, while earnings growth is listed as N/A due to the absence of positive earnings in the prior year for comparison. The fact that revenue is growing while earnings remain negative implies that the company is expanding its top line but has not yet achieved the profitability required to match that growth rate. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that all available cash flow is retained within the business to fund operations and potential growth initiatives. Consequently, the company reinvests its earnings, specifically the $950,669 in free cash flow, into growth rather than distributing income to shareholders. Overall, the growth and income profile presents a high-risk scenario where significant revenue expansion is occurring alongside negative profitability and no income distribution to investors.